

1 **Full title: Epidemic Persistence: Equilibria and Stability Analysis of Spread Process**
2 **Dynamics over Networks, with Asymptomatic Carriers and Heterogeneous Model**
3 **Parameters**

5 **Short title: Epidemic persistence: an analysis of spread process dynamics with**
6 **asymptomatic carriers**

8 **Xiaoqi Bi^{1*}, Carolyn L. Beck¹**

11 ¹ Coordinated Science Laboratory and Department of Industrial & Enterprise Systems Engineering, University of
12 Illinois at Urbana-Champaign, Urbana, Illinois, United States of America

14 * Corresponding author

15 E-mail: xiaoqib2@illinois.edu

Abstract

We present an analysis of epidemiological compartment models that explicitly capture the dynamics of asymptomatic but infectious individuals. Our models can be viewed as an extension to classic SIR models, to which a distinct Asymptomatic compartment is added. We discuss both a group compartment model capturing a Susceptible-Asymptomatic-Infected-Recovered-Susceptible (SAIRS) epidemic process, and also introduce and evaluate SAIRS dynamics evolving over networks. We investigate equilibria and stability properties that include both disease-free and endemic equilibria states for these models, providing sufficient conditions for convergence to these equilibria. Model parameter estimation results based on local test-site and Peoria county clinic data are given, and a number of simulations illustrating the effects of asymptomatic-infected individuals and network structure on the spread and/or persistence of the disease are presented.

Keywords: Epidemic dynamics, networks, data-informed modeling, stability analysis, parameter estimation

1 Introduction

Modeling, analysis and control of epidemic spread processes over networks have been of interest in multiple communities over the past two decades, owing not only to the COVID-19 pandemic, but also to outbreaks of the related SARS and MERS viruses, Zika, Ebola, and more generally, computer network viruses and propagating opinions over social media networks. Conducting experiments to analyze infectious disease spread processes and response policies are prohibitive for many reasons, including not only costs, but more importantly ethics. As a result, mathematical modeling and simulation approaches provide essential alternatives for estimating and predicting when and how an epidemic might spread over a contact network [1]. Further, simulations of strategic control policies for validated epidemic models can provide insights into approaches for mitigating virus spread over networks [2].

The mathematical models for most epidemiological studies today derive from the *compartment models* first proposed by Kermack and McKendrick [3], although mathematical models for epidemics, or spread processes more generally, have been analyzed and studied for over 200 years, with one of the earliest known studies in the literature being that by D. Bernoulli on the analysis of the small-pox virus [4]. The now widely used compartment models assume every subject lies in a specific segment or compartment of the population at any given time, with these compartments including *susceptible* (S), *infected* (I), *exposed* (E) and/or *recovered* (R) population groups, leading to the

42 classical epidemiological models: SI (susceptible-infected), SIS (susceptible-infected-susceptible), SIR (susceptible-
43 infected-recovered) and SEIR (susceptible-exposed-infected-recovered) models. As one example, the Kermack and
44 McKendrick SIS model is given by

$$\begin{aligned} \dot{S}(t) &= -\beta S(t)I(t) + \delta I(t) \\ \dot{I}(t) &= \beta S(t)I(t) - \delta I(t), \end{aligned} \tag{1}$$

46 where $S(t)$ is the susceptible (non-infected) segment of the population at time t , $I(t)$ is the infected segment of the
47 population at time t , β represents the rate of infection or contact amongst infected and susceptible subgroups, and δ
48 represents the healing rate. This foundational model assumes: (1) a homogeneous population with no vital dynamics,
49 that is birth and death processes are not included, meaning that infection and healing are assumed to occur at faster
50 rates than vital dynamics and the population size is assumed to remain constant; and (2) the population mixes over a
51 trivial network, or in other words, over a complete graph structure. These assumptions have led to errors in previous
52 epidemic forecasts [5].

53 We note that similar models to that given in (1) have been derived for SI, SIR(S) and SEIR(S) processes; SI
54 models simply have $\delta = 0$; SIR(S) models include a recovered segment of the population and a recovery rate γ ;
55 and SEIR(S) models include an exposed segment of the population and a corresponding parameter σ capturing the
56 rate at which an exposed individual transitions to the infected state; the exposed segment is typically assumed to be
57 non-infectious with the accompanying rate parameter capturing the disease incubation period. There are numerous
58 variants of these models, including recent models in which human awareness is taken into account [6–9], and in which
59 multiple epidemic processes or epidemic processes with heterogeneous or non-static parameters may be propagating
60 simultaneously [10–13].

61 Over the past two decades, both to address the discrepancies found in prior epidemic forecasts, and to better model
62 spreading processes of computer viruses over communication networks, there has been an increased focus on the
63 study of epidemic processes evolving over arbitrary network, or graph, structures; see for example [14–18], and from
64 a controls perspective [19–21] (as the literature in this area is vast this list is not exhaustive). These networks represent
65 the variation in interactions among members of a population, where the nodes in the network may represent either
66 individuals or subgroups in the larger population, and the edges between nodes in the network represent the strength
67 of the interaction between the nodes.

68 Over a network of n total nodes, epidemic or spread process dynamics can be described by Markov process models,
69 for example, of dimension 2^n for SIS models and 3^n for SIR models. These models describe the probability of
70 each node transitioning from susceptible to infected, and/or to recovered states, and back, where the probabilities are
71 determined by the model rate parameters (infection, healing, etc.) and the network interconnection structure, and
72 reflect the stochastic evolution of such epidemic processes. Clearly, as the number n of nodes in the network increase,
73 analysis of these models becomes intractable. As an alternative, *mean-field approximation* (MFA) models have been
74 derived and shown to be appropriate under certain assumptions; these models are derived by taking expectations over
75 infection transition rates of the agents and rely on the fundamental work of Feller [22] and Kurtz [23].

76 When individuals or population subgroups are assumed to be interconnected via a graph with adjacency matrix
77 $W = [W_{ij}]$, where element W_{ij} defines the strength of the connection from node i to node j , and further making as-
78 sumptions of large and constant agent population size and probabilistic independence assumptions, the deterministic
79 networked MFA dynamic models are now considered standard models; these models have been analyzed in detail and
80 shown to provide upper bounds on the probability of infection of a given agent at any given time (see [24] and [25]
81 for discussions and perspectives). Again considering an SIS process example, denoting the probability of node i being
82 infected at time t by $p_i(t) \in [0, 1]$, the following differential equation provides a MFA model of the evolution of the
83 probabilities of infection of the nodes:

$$84 \quad \dot{p}_i(t) = (1 - p_i(t))\beta \sum_{j=1}^N W_{ij}p_j(t) - \delta p_i(t). \quad (2)$$

85 This model provides a lower complexity deterministic approximation to the full dimension Markov process model of
86 a SIS spread process evolving over a static network. Further details can be found in [19,26,27]. Discrete time versions
87 of these approximation models have also been proposed and studied, see for example [28,29].

88 The main objectives in most analyses of epidemic process dynamics include computing the system equilibria, and
89 determining the convergence behavior of these processes near the equilibria. In particular, conditions for the existence
90 of and convergence to “disease-free” or “endemic” equilibria are sought. For (2), it is straightforward to see that
91 the disease-free state, $p_i^* = 0$ for all $i \in \{1, \dots, N\}$, is a trivial equilibrium of the dynamics. It has been shown that
92 this equilibrium is globally asymptotically stable if and only if $\frac{\beta}{\delta} \leq \frac{1}{\lambda_{\max}(W)}$, where $\lambda_{\max}(W)$ represents the largest
93 real-valued part of the eigenvalues of the matrix W . It has further been shown, however, that if $\frac{\beta}{\delta} > \frac{1}{\lambda_{\max}(W)}$, then

94 there exists another equilibrium that is (almost) globally asymptotically stable, with $p_i^* \in (0, 1)$ for all $i \in \{1, 2, \dots, n\}$,
95 implying the system converges asymptotically to an *endemic* state [28, 30–32].

96 In this paper we consider a compartment model structure that specifically accounts for *infectious but asymptomatic*
97 subgroups or individuals, namely a SAIRS model structure, incorporating Susceptible(S), Asymptomatic-infected(A),
98 Infected-symptomatic(I), and Recovered(R) subsets of the population. We note that the asymptomatic subset we
99 consider may include those individuals who do not experience symptoms through the course of their infection, as
100 well as pre-symptomatic individuals. This structure may be used to directly capture the dynamics of COVID-19
101 and the role asymptomatic individuals play in the disease spread process; this model was first introduced in public
102 online seminars and panel discussions in [33, 34], and in the literature in [20, 35]. Compartment models with different
103 structures but including explicit asymptomatic population segments were previously proposed for dengue fever [36]
104 and rumor spreading over online social networks [37]. Relevant work on alternative SAIRS model structures has been
105 reported in [38–41]. In [38], the authors derive mean-field approximations of the exact state evolution for SAIRS
106 models, and also present a game-theoretic model where nodes choose their activation probabilities in a strategic (e.g.,
107 selfish) manner using current state information as feedback. The author in [39] introduces a compartmental model
108 including a group of individuals with pure asymptomatic infection (i.e., having no symptoms throughout the course
109 of infection), with permanent immunity upon recovery, and provides estimations of the asymptomatic populations in
110 California, Florida, New York, and Texas. The authors in [40] present a more complex data-informed model including
111 pre-symptomatic, asymptomatic, and hospitalized subgroups of the population, and provide forecasts for the epidemic
112 over homogeneous populations. In [41] the authors provide \mathcal{H}_∞ based (i.e., worst-case) stability analyses for an SAIR
113 model structure, and provide more focused simulations for SAIR spread processes over small-world networks; there
114 is no explicit loss of immunity included in their model under which to study endemicity behavior. Herein we provide
115 more thorough stability analyses and simulations of the endemic equilibria for SAIRS models (as well as for the
116 disease free equilibria), than have been presented in prior work. Our analysis approach is based on classic Lyapunov
117 methods for dynamical systems. We further take the contact network into consideration and discuss the impact of the
118 network structure and potentially heterogeneous epidemic parameters on the spread process.

119 In the remainder of the paper, we first present the specific SAIRS group and networked models we will consider
120 throughout, and discuss the equilibria and stability properties of these models in Section 2. In Section 3, we dis-

121 cuss a simple least squares estimation approach to compute the SAIRS model parameters from data, which relies on
122 knowledge of the proportion, q , of the infections that are asymptomatic. We therefore also discuss methods for es-
123 timating this proportion, and use local COVID test-site data (Champaign County Public Health District) to evaluate
124 the results. These initial estimation results are compared to data recorded at Peoria County clinics from April 2020
125 to July 2020, which explicitly includes symptoms of all sample individuals. We then discuss a series of simulation
126 studies in Section 4, which illustrate our stability results as well as highlighting the role the asymptomatic subgroup
127 and the contact network play in disease spread under various quarantine policies made with and without awareness
128 of asymptomatic status. We further present a longer-term forecast for the epidemic process with both pharmaceutical
129 and non-pharmaceutical mitigation approaches. To conclude, we discuss the challenges the currently available data
130 present and our ongoing and future work in Section 5.

131 **2 The SAIRS model**

132 In order to investigate the effects of asymptomatic individuals on the spread of the epidemic, we consider the effects of
133 a proportion of the infected subgroup being asymptomatic and potentially unaware of their carrier status. We evaluate
134 both single group models as well as networked models, providing equilibria and stability analyses.

135 **2.1 Single-Group and Networked Models**

136 Let $S(t), A(t), I(t), R(t)$, respectively, represent the proportion of susceptible, asymptomatic-infected, symptomatic-
137 infected, and recovered individuals at time t . The Group SAIR(S) model we consider is characterized as:

$$\begin{aligned} \dot{S}(t) &= -\beta S(t)(A(t) + I(t)) + \delta R(t) \\ \dot{A}(t) &= q\beta S(t)(A(t) + I(t)) - \sigma A(t) - \kappa A(t) \\ \dot{I}(t) &= (1 - q)\beta S(t)(A(t) + I(t)) + \sigma A(t) - \gamma I(t) \\ \dot{R}(t) &= \kappa A(t) + \gamma I(t) - \delta R(t). \end{aligned} \tag{3}$$

139 Here again β is the transmission rate amongst susceptible and infected groups, the latter of which includes both asymp-
140 tomatic and symptomatic; κ and γ , respectively, are the recovery rates for asymptomatic-infected and symptomatic-

141 infected groups. The proportion of infections that are asymptomatic (and/or pre-symptomatic) is denoted by q , after
 142 which the newly infected individuals show no symptom but are still infectious; correspondingly, $(1 - q)$ represents the
 143 proportion of symptomatic infections. Further, σ is the progression rate from asymptomatic (and/or pre-symptomatic)
 144 to symptomatic, and δ represents the rate at which immunity recedes. When $\delta = 0$, individuals gain permanent
 145 immunity to the infection upon recovery. We assume these relations hold for all $t \geq 0$.

146 We also study the SAIRS model dynamics of n agents (individuals or subpopulations) interconnected over an
 147 arbitrary network structure, with adjacency matrix denoted by W . Defining s_i, a_i, p_i, r_i , respectively, as the proportion
 148 of the subpopulation i that is susceptible (or healthy), asymptomatic-infected, symptomatic-infected, or recovered, the
 149 Networked SAIRS (N-SAIRS) dynamics over an arbitrary interconnection network is given by

$$\begin{aligned}
 \dot{s}_i(t) &= -\beta_i s_i(t) \sum_j W_{ij} (a_j(t) + p_j(t)) + \delta_i r_i(t) \\
 \dot{a}_i(t) &= q \beta_i s_i(t) \sum_j W_{ij} (a_j(t) + p_j(t)) - \sigma_i a_i(t) - \kappa_i a_i(t) \\
 \dot{p}_i(t) &= (1 - q) \beta_i s_i(t) \sum_j W_{ij} (a_j(t) + p_j(t)) + \sigma_i a_i(t) - \gamma_i p_i(t) \\
 \dot{r}_i(t) &= \kappa_i a_i(t) + \gamma_i p_i(t) - \delta_i r_i(t),
 \end{aligned}
 \tag{4}$$

151 where, similar to the Group Model (3), for a subpopulation i , β_i is the agent-to-agent transmission rate; κ_i and γ_i ,
 152 respectively, are the recovery rates for asymptomatic-infected and symptomatic-infected subsets; again, σ_i represents
 153 the transition rate from asymptomatic to symptomatic infected; and δ_i represents the rate at which individuals may be
 154 susceptible to reinfection again after recovery. Since all individuals in a subgroup i will reside in one of these subsets,
 155 we have $s_i(t) + a_i(t) + p_i(t) + r_i(t) = 1$, over all $i \in [n]$. This proportion is relative to the subpopulation size, N_i of
 156 group i ; recall the total population $N = \sum_i N_i$.

157 **Remark:** In the case where we have homogeneous spread parameters and the underlying network topology is com-
 158 plete with evenly distributed interconnection weights, that is, when $W_{ij} = 1/n$ for all $i, j \in [n]$, and $(\beta_i, \kappa_i, \gamma_i, \sigma_i, \delta_i) =$
 159 $(\beta, \kappa, \gamma, \sigma, \delta)$ for all $i \in [n]$, the Group Model (3) and the Networked Model (4) are equivalent.

160 Prior to discussing the analysis of equilibria and stability for these models, we note the following result which
 161 establishes that the N-SAIRS model is well-defined. This result was first presented in [20] for the discrete-time case
 162 using an induction argument; it is straightforward to adapt this result to the continuous-time model given in (4). We

163 first state our assumption on the model parameters.

164 **Assumption 1.** For all $i, j \in [n]$, we have $\beta_i, \gamma_i, \delta_i, \sigma_i, \kappa_i, W_{ij} \geq 0, 0 \leq q \leq 1$.

165 **Lemma 1.** Consider the model in (4) under Assumption 1. Suppose $s_i(0), a_i(0), p_i(0), r_i(0) \in [0, 1], s_i(0) + a_i(0) +$
 166 $p_i(0) + r_i(0) = 1, \forall i \in [n]$. Then, for all $t \geq 0$ and $i \in [n]$, we have $s_i(t), a_i(t), p_i(t), r_i(t) \in [0, 1]$ and $s_i(t) + a_i(t) +$
 167 $p_i(t) + r_i(t) = 1$.

168 *Proof:* We show that for all $i \in [n]$ and $t \geq 0$, when $s_i(t) = 0, a_i(t) = 0, p_i(t) = 0, r_i(t) = 0$, respectively, we
 169 have $\dot{s}_i(t) \geq 0, \dot{a}_i(t) \geq 0, \dot{p}_i(t) \geq 0, \dot{r}_i(t) \geq 0$; and when $s_i(t) = 1, a_i(t) = 1, p_i(t) = 1, r_i(t) = 1$, respectively, we have
 170 $\dot{s}_i(t) \leq 0, \dot{a}_i(t) \leq 0, \dot{p}_i(t) \leq 0, \dot{r}_i(t) \leq 0$.

171 Firstly, from $s_i(0) + a_i(0) + p_i(0) + r_i(0) = 1$, and $\dot{s}_i(t) + \dot{a}_i(t) + \dot{p}_i(t) + \dot{r}_i(t) = 0$, we have $s_i(t) + a_i(t) + p_i(t) +$
 172 $r_i(t) = 1, \forall i \in [n], \forall t \geq 0$.

173 By Assumption 1 and (4), for all $i \in [n]$, if $s_i(0) = 0$, we have $\dot{s}_i(0) = \delta_i r_i(0) \geq 0$. By the continuity of $s_i(t)$,
 174 there exists $T_{s_i} \geq 0$, such that, $s_i(t) \geq 0, \forall t \in [0, T_{s_i}]$. Similarly, if $a_i(0) = 0$, we have $\dot{a}_i(0) = q\beta_i s_i(0) \sum_j W_{ij} (a_j(0) +$
 175 $p_j(0)) \geq 0$; if $p_i(0) = 0$, we have $\dot{p}_i(0) = (1 - q)\beta_i s_i(0) \sum_j W_{ij} (a_j(0) + p_j(0)) + \sigma_i a_i(0) \geq 0$; and if $r_i(0) = 0$, we
 176 have $\dot{r}_i(0) = \kappa_i a_i(0) + \gamma_i p_i(0) \geq 0$. Thus, there also exist $T_{a_i} \geq 0, T_{p_i} \geq 0, T_{r_i} \geq 0$, respectively, such that $a_i(t) \geq 0,$
 177 $\forall t \in [0, T_{a_i}]; p_i(t) \geq 0, \forall t \in [0, T_{p_i}]; r_i(t) \geq 0, \forall t \in [0, T_{r_i}]$.

178 Define $T := \min_{i \in [n]} \min(T_{s_i}, T_{a_i}, T_{p_i}, T_{r_i})$ for $i \in [n]$. Then by definition, $s_i(T) \geq 0, a_i(T) \geq 0, p_i(T) \geq 0, r_i(T) \geq$
 179 $0, \forall i \in [n]$. Similarly, we have $\dot{s}_i(T) = \delta_i r_i(T) \geq 0$ if $s_i(T) = 0; \dot{a}_i(T) = q\beta_i s_i(T) \sum_j W_{ij} (a_j(T) + p_j(T)) \geq 0$ if $a_i(T) =$
 180 $0; \dot{p}_i(T) = (1 - q)\beta_i s_i(T) \sum_j W_{ij} (a_j(T) + p_j(T)) + \sigma_i a_i(T) \geq 0$ if $p_i(T) = 0; \dot{r}_i(T) = \kappa_i a_i(T) + \gamma_i p_i(T) \geq 0$ if $r_i(T) = 0$.
 181 Thus, for all $t \geq 0$ such that $s_i(t) = 0, a_i(t) = 0, p_i(t) = 0$ or $r_i(t) = 0$, respectively, we have $\dot{s}_i(t) \geq 0, \dot{a}_i(t) \geq 0, \dot{p}_i(t) \geq$
 182 $0, \dot{r}_i(t) \geq 0$. This further suggests that, $s_i(t) \geq 0, a_i(t) \geq 0, p_i(t) \geq 0, r_i(t) \geq 0, \forall i \in [n], \forall t \geq 0$.

183 Next, we prove that if $s_i(t) = 1, a_i(t) = 1, p_i(t) = 1$, or $r_i(t) = 1$, respectively, we have $\dot{s}_i(t) \leq 0, \dot{a}_i(t) \leq 0, \dot{p}_i(t) \leq$
 184 $0, \dot{r}_i(t) \leq 0$. Given in Lemma 1, $s_i(t) + a_i(t) + p_i(t) + r_i(t) = 1$, and $s_i(t), a_i(t), p_i(t), r_i(t) \geq 0, \forall i \in [n]$. Hence, if
 185 $s_i(t) = 1$, we have $a_i(t) = 0, p_i(t) = 0, r_i(t) = 0$, which leads to $\dot{s}_i(t) = -\beta_i \sum_j W_{ij} (a_j(t) + p_j(t)) \leq 0$. Similarly, if
 186 $a_i(t) = 1$, we have $\dot{a}_i(t) = -\sigma_i - \kappa_i \leq 0$; if $p_i(t) = 1, \dot{p}_i(t) = -\gamma_i \leq 0$; and if $r_i(t) = 1, \dot{r}_i(t) = -\delta_i \leq 0$. Similar to the
 187 preceding argument, we have $s_i(t) \leq 1, a_i(t) \leq 1, p_i(t) \leq 1, r_i(t) \leq 1, \forall i \in [n], \forall t \geq 0$. ■

188 2.2 Equilibria and stability

189 To quantitatively and qualitatively evaluate the propagation of the virus, a critical threshold quantity, denoted by R_0
 190 and referred to as the basic reproduction number, is used extensively in epidemiological studies. This number indicates
 191 how rapidly infected individuals transmit the virus to healthy individuals. In this section, we evaluate the SAIRS model
 192 equilibria and conduct stability analyses around the equilibria, leading to conditions on R_0 which provide quantitative
 193 criteria for convergence to the disease-free state, or to an endemic state. We first consider the group model.

194 2.2.1 Group Model SAIRS

195

196 Noting that $S(t) = 1 - A(t) - I(t) - R(t)$, the nonlinear system dynamics (3) can be written as

$$\begin{aligned} \dot{A}(t) &= q\beta(1 - A(t) - I(t) - R(t))(A(t) + I(t)) - \sigma A(t) - \kappa A(t) \\ \dot{I}(t) &= (1 - q)\beta(1 - A(t) - I(t) - R(t))(A(t) + I(t)) + \sigma A(t) - \gamma I(t) \\ \dot{R}(t) &= \kappa A(t) + \gamma I(t) - \delta R(t). \end{aligned}$$

197

198 By setting $\dot{A}(t), \dot{I}(t), \dot{R}(t)$ to 0, we can see immediately that an equilibrium state of system (5) is given by $(A^e, I^e, R^e) =$
 199 $(0, 0, 0)$ with $S^e = 1$. This is the disease-free equilibrium (DFE) in the case of non-permanent immunity. Linearizing
 200 system (5) around (A^e, I^e, R^e) , we obtain the system Jacobian matrix,

$$J^e = \begin{bmatrix} q\beta - \kappa - \sigma & q\beta & 0 \\ (1 - q)\beta + \sigma & (1 - q)\beta - \gamma & 0 \\ \kappa & \gamma & -\delta \end{bmatrix}. \quad (5)$$

201

202 The system described by (5) is globally asymptotically stable around the DFE if all eigenvalues of J^e have negative real
 203 parts; see Theorem 4.7 from [42]. Computing the characteristic polynomial for J^e , we have after some straightforward
 204 manipulations,

$$\det(\lambda I - J^e) = (\lambda + \delta) \cdot [(\lambda - q\beta + \kappa + \sigma)(\lambda - (1 - q)\beta + \gamma) - q(1 - q)\beta^2 - q\beta\sigma] \quad (6)$$

205

206 Applying the Routh-Hurwitz criterion to (6) gives us the following.

207 **Proposition 1.** *Given the system dynamics defined by (5), the DFE $(S^e, A^e, I^e, R^e) = (1, 0, 0, 0)$ is globally asymptoti-*
 208 *cally stable (GAS) when $\delta > 0$ and*

$$209 \quad R_0 := \max \left(\frac{\beta}{\kappa + \gamma + \sigma}, \frac{\beta(q\gamma + (1-q)\kappa + \sigma)}{\gamma(\kappa + \sigma)} \right) < 1. \quad (7)$$

210 In the case where $\delta = 0$, that is when immunity following recovery from infection is permanent, the disease-free
 211 equilibria will be the subspace of points $(S^e, A^e, I^e, R^e) = (c_S, 0, 0, c_R)$, where constants c_R, c_S satisfy $c_S + c_R = 1$. An-
 212 alyzing the Jacobian for (5) in this case gives us that the equilibria $(S^e, A^e, I^e, R^e) = (c_S, 0, 0, c_R)$ are also globally
 213 asymptotically stable (GAS) when (7) is satisfied. That is, this basic reproduction number expression provides an ap-
 214 propriate threshold for determining when the spread process for the SAIRS model will or will not spread exponentially
 215 in either of the scenarios of permanent or non-permanent immunity.

216 We may also consider the case where the asymptomatic-infected and symptomatic-infected individuals have dif-
 217 ferent infection transmission rates. In the case of COVID-19, this difference could be partly due to the inability to
 218 conduct frequent large-scale population testing, for example allowing efficient identification and isolation of Asymp-
 219 tomatic individuals. Thus, we would have different quarantine control effectiveness over these two subpopulations. In
 220 this case, we denote the infection transmission rates for agent-to-agent contact between the susceptible subgroup and
 221 the two infectious groups, respectively, as β_A, β_I . As in the preceding analysis, we compute the Jacobian around the
 222 disease-free equilibrium $(S^e, A^e, I^e, R^e) = (1, 0, 0, 0)$, as

$$223 \quad J^e = \begin{bmatrix} q\beta_A - \kappa - \sigma & q\beta_I & 0 \\ (1-q)\beta_A + \sigma & (1-q)\beta_I - \gamma & 0 \\ \kappa & \gamma & -\delta \end{bmatrix}. \quad (8)$$

224 Following a similar approach as before yields

$$225 \quad R_0 := \max \left(\frac{q\beta_A + (1-q)\beta_I}{\kappa + \gamma + \sigma}, \frac{q\beta_A\gamma + \beta_I((1-q)\kappa + \sigma)}{\gamma(\kappa + \sigma)} \right). \quad (9)$$

226 For GAS, using a similar argument, we can again show it is required that $R_0 < 1$.

227 Of perhaps greater interest is the endemic equilibria for (5). If we again assume non-permanent immunity, that is,
 228 $\delta > 0$, setting $\dot{A}(t), \dot{I}(t), \dot{R}(t)$ to 0, we can compute the unique endemic equilibrium for (5):

$$\begin{matrix} 229 \\ \\ \\ \end{matrix} \begin{bmatrix} S^e \\ A^e \\ I^e \\ R^e \end{bmatrix} = \begin{bmatrix} \frac{\gamma(\kappa+\sigma)}{\beta(q\gamma+(1-q)\kappa+\sigma)} \\ \frac{q\delta\gamma(\beta(q\gamma+(1-q)\kappa+\sigma)-\gamma(\kappa+\sigma))}{\beta(q\gamma+(1-q)\kappa+\sigma)(\gamma(\kappa+\sigma)+\delta(q\gamma+(1-q)\kappa+\sigma))} \\ \frac{\delta((1-q)\kappa+\sigma)(\beta(q\gamma+(1-q)\kappa+\sigma)-\gamma(\kappa+\sigma))}{\beta(q\gamma+(1-q)\kappa+\sigma)(\gamma(\kappa+\sigma)+\delta(q\gamma+(1-q)\kappa+\sigma))} \\ \frac{\gamma(\kappa+\sigma)(\beta(q\gamma+(1-q)\kappa+\sigma)-\gamma(\kappa+\sigma))}{\beta(q\gamma+(1-q)\kappa+\sigma)(\gamma(\kappa+\sigma)+\delta(q\gamma+(1-q)\kappa+\sigma))} \end{bmatrix}. \quad (10)$$

230 Denoting $\Psi = \gamma(\kappa + \sigma)$ and $\Phi = q\gamma + (1 - q)\kappa + \sigma$, and noting that both $\Psi > 0$ and $\Phi > 0$, we further define

$$\begin{matrix} 231 \\ \\ \end{matrix} \begin{aligned} C &= \beta\Phi - \Psi = \beta(q\gamma + (1 - q)\kappa + \sigma) - \gamma(\kappa + \sigma), \\ D &= \delta\Phi + \Psi = \delta(q\gamma + (1 - q)\kappa + \sigma) + \gamma(\kappa + \sigma) > 0. \end{aligned} \quad (11)$$

232 The endemic equilibrium now can be written more compactly as

$$\begin{matrix} 233 \\ \\ \\ \end{matrix} \begin{bmatrix} S^e \\ A^e \\ I^e \\ R^e \end{bmatrix} = \begin{bmatrix} \frac{\Psi}{\beta\Phi} \\ \frac{q\delta\gamma C}{\beta\Phi D} \\ \frac{\delta((1-q)\kappa+\sigma)C}{\beta\Phi D} \\ \frac{\Psi C}{\beta\Phi D} \end{bmatrix}. \quad (12)$$

234 Using the relationship $S(t) = 1 - A(t) - I(t) - R(t)$ and the expression for the endemic equilibrium point in (12), we

235 compute the Jacobian around this equilibrium point as

$$236 \quad J^e = \begin{bmatrix} J_1 & J_2 & J_3 \\ J_4 & J_5 & J_6 \\ J_7 & J_8 & J_9 \end{bmatrix} = \begin{bmatrix} -\frac{(\kappa+\sigma)((1-q)\kappa+\sigma)}{\Phi} - \frac{q\delta C}{D} & \frac{q\Psi}{\Phi} - \frac{q\delta C}{D} & -\frac{q\delta C}{D} \\ \frac{(\gamma+\sigma)((1-q)\kappa+\sigma)}{\Phi} - \frac{(1-q)\delta C}{D} & -\frac{q\gamma(\gamma+\sigma)}{\Phi} - \frac{(1-q)\delta C}{D} & -\frac{(1-q)\delta C}{D} \\ \kappa & \gamma & -\delta \end{bmatrix}. \quad (13)$$

237 We can then show the following stability result using the Routh-Hurwitz criterion and algebraic manipulations.

238 **Proposition 2.** *Given the system with dynamics defined by (5), with endemic equilibrium (12), and C and D as defined*
 239 *in (11) and (13) respectively, if both $C > 0$ and*

$$240 \quad \frac{(CD + D^2)(\delta + F)\Phi(F\Phi - \Psi) - D^2\Psi(F\Phi - \Psi) + \delta(\delta + F)(C^2 + CD)\Phi^2 + \delta CD\Phi(F\Phi - \Phi^2 - \Psi)}{CD\Psi\Phi^2} > 1, \quad (14)$$

241 where $F = \gamma + \kappa + \sigma$, then the system asymptotically converges to the endemic equilibrium.

242 *Proof:* Note that the characteristic polynomial for J^e is given by

$$243 \quad \det(\lambda I - J^e) = (\lambda - J_1)(\lambda - J_5)(\lambda - J_9) - J_3J_7(\lambda - J_5) - J_2J_4(\lambda - J_9) - J_6J_8(\lambda - J_1) - (J_2J_6J_7 + J_3J_4J_8) \\ = \lambda^3 + a_1\lambda^2 + a_2\lambda + a_3. \quad (15)$$

244 Applying the Routh-Hurwitz criteria to (15), for all roots of the polynomial to have negative real parts, we require

245 $a_1, a_3 > 0$, and $a_1a_2 > a_3$. Assuming

$$246 \quad C = \beta\Phi - \Psi > 0, \quad (16)$$

247 we have, $J_1, J_5 < 0$, $J_3, J_6, J_9 \leq 0$, and $J_7, J_8 \geq 0$. Consequently,

$$\begin{aligned}
 a_1 &= -(J_1 + J_5 + J_9) > 0, \\
 a_2 &= J_9(J_1 + J_5) + (J_1J_5 - J_2J_4) - (J_3J_7 + J_6J_8) > 0 \\
 a_3 &= J_7(J_3J_5 - J_2J_6) + J_8(J_1J_6 - J_3J_4) + J_9(J_2J_4 - J_1J_5) \\
 &= J_7 \frac{q\delta\gamma C}{D} + J_8 \frac{\delta C((1-q)k + \sigma)}{D} - J_9 \frac{\delta C\Phi}{D} > 0.
 \end{aligned}
 \tag{17}$$

249 To satisfy the condition $a_1a_2 > a_3$, we equivalently require

$$\begin{aligned}
 &a_1a_2 - a_3 \\
 &= (J_1 + J_5)[J_3J_7 + J_6J_8 + J_2J_4 - J_1J_5 - J_9(J_1 + J_5) - J_9^2] + J_7(J_2J_6 - J_3J_5) + J_8(J_3J_4 - J_1J_6) + J_9(J_3J_7 + J_6J_8) > 0.
 \end{aligned}
 \tag{18}$$

251 After many tedious algebraic manipulations we can show that satisfying (18) is equivalent to satisfying the condition

$$\frac{(CD + D^2)(\delta + F)\Phi(F\Phi - \Psi) - D^2\Psi(F\Phi - \Psi) + \delta(\delta + F)(C^2 + CD)\Phi^2 + \delta CD\Phi(F\Phi - \Phi^2 - \Psi)}{CD\Psi\Phi^2} > 1. \tag{19}$$

253 ■

254 Inequalities (16) and (19) provide a sufficient condition for asymptotic stability of the endemic equilibrium. Simu-
 255 lations illustrating the behavior of the SAIRS model dynamics when conditions for asymptotic stability to the endemic
 256 equilibrium are met are given in Section 4.

257 2.2.2 Networked Model N-SAIRS

258

259 We now evaluate equilibria and their stability properties for the networked SAIRS models. Given $s_i(t) = 1 - a_i(t) -$

260 $p_i(t) - r_i(t)$ for all $t \geq 0$, $i \in [n]$, system (4) can be represented in matrix form as

$$\begin{aligned}
 \dot{a}(t) &= [q(I - A(t) - P(t) - R(t))BW - \Sigma - K]a(t) + q[I - A(t) - P(t) - R(t)]BWp(t) \\
 \dot{p}(t) &= [(1 - q)(I - A(t) - P(t) - R(t))BW + \Sigma]a(t) + [(1 - q)(I - A(t) - P(t) - R(t))BW - \Gamma]p(t) \\
 \dot{r}(t) &= Ka(t) + \Gamma p(t) - \Delta r(t).
 \end{aligned} \tag{20}$$

262 Here,

$$a(t) = \begin{bmatrix} a_1(t) \\ \vdots \\ a_n(t) \end{bmatrix}, \quad p(t) = \begin{bmatrix} p_1(t) \\ \vdots \\ p_n(t) \end{bmatrix}, \quad r(t) = \begin{bmatrix} r_1(t) \\ \vdots \\ r_n(t) \end{bmatrix}, \tag{21}$$

264 with $n \times n$ matrices $A(t) = \text{diag}(a_i(t))$, $P(t) = \text{diag}(p_i(t))$, $R(t) = \text{diag}(r_i(t))$, $B = \text{diag}(\beta_i)$, $K = \text{diag}(\kappa_i)$, $\Gamma =$
 265 $\text{diag}(\gamma_i)$, $\Sigma = \text{diag}(\sigma_i)$, $\Delta = \text{diag}(\delta_i)$, and adjacency matrix W .

266 We first consider the case with permanent immunity, i.e., $\delta_i = 0$. Setting $\dot{a}(t), \dot{p}(t), \dot{r}(t)$ to 0, we can compute
 267 the equilibrium state where $a^e = p^e = \bar{0}$, $r^e = \bar{r}_c$, where \bar{r}_c is a non-negative constant vector with elements $r_{c_i} < 1$.
 268 Linearizing the system (20) at the equilibrium (a^e, p^e, r^e) , we obtain the $3n \times 3n$ system Jacobian Matrix given by

$$J^e = \begin{bmatrix} q(I - R_c)BW - \Sigma - K & q(I - R_c)BW & 0 \\ (1 - q)(I - R_c)BW + \Sigma & (1 - q)(I - R_c)BW - \Gamma & 0 \\ K & \Gamma & -\Delta \end{bmatrix}. \tag{22}$$

270 Analysis of this Jacobian matrix will lead to a constraint on the spectrum of the weighting matrix W , which if met
 271 guarantees the system is at least locally asymptotically stable at the DFE. An alternative is to consider a Lyapunov
 272 stability analysis approach, which may provide global results. Specifically, if we consider a quadratic Lyapunov
 273 function, we can show the following.

274 **Theorem 1.** For the system given by (20), under Assumption 1, the DFE $(a^e, p^e, r^e) = (0, 0, \bar{r}_c)$ is globally asymptoti-
 275 cally stable (GAS) if

$$\begin{bmatrix} qW & \frac{1}{2}W \\ \frac{1}{2}W & (1 - q)W \end{bmatrix} \prec \begin{bmatrix} B^{-1}(\Sigma + K) & -\frac{1}{2}B^{-1}\Sigma \\ -\frac{1}{2}B^{-1}\Sigma & B^{-1}\Gamma \end{bmatrix}, \tag{23}$$

277 where \prec denotes relative definiteness of the matrices.

278 *Proof:* We now consider non-permanent immunity ($\Delta > 0$), thus $r_c = 0$. Consider the Lyapunov function

$$279 \quad V(a, p, r) = \frac{1}{2\alpha} (a^T B^{-1} a + p^T B^{-1} p) + \frac{1}{2} r^T r. \quad (24)$$

280 Clearly, $V > 0$ for all $(a, p, r) \neq 0$ and

$$281 \quad \left\| \begin{bmatrix} a \\ p \\ r \end{bmatrix} \right\| \rightarrow \infty \implies V(a, p, r) \rightarrow \infty. \quad (25)$$

282 Computing the derivative, we have

$$\begin{aligned} \dot{V} &= \frac{1}{\alpha} (a^T B^{-1} \dot{a} + p^T B^{-1} \dot{p}) + r^T \dot{r} \\ &= \frac{1}{\alpha} a^T B^{-1} q \{([I - A - P - R]BW - \Sigma - K)a + [I - A - P - R]BW p\} \\ &\quad + \frac{1}{\alpha} p^T B^{-1} (1 - q) \{([I - A - P - R]BW + \Sigma)a + ([I - A - P - R]BW - \Gamma)p\} \\ &\quad + r^T \{Ka + \Gamma p - \Delta r\}. \end{aligned} \quad (26)$$

Since A , P and R are diagonal matrices with $0 \leq a_i \leq 1$, $0 \leq p_j \leq 1$, and $0 \leq r_k \leq 1$ for all $i, j, k = 1, \dots, n$, and we know all elements of Σ , K , Γ and Δ are non-negative, then it is straightforward to see

$$\dot{V} \leq \frac{1}{\alpha} a^T [qW - B^{-1}(\Sigma + K)a + qWp] + \frac{1}{\alpha} p^T [((1 - q)W - B^{-1}\Sigma)a + ((1 - q)W - B^{-1}\Gamma)p] + r^T [Ka + \Gamma p - \Delta r]. \quad (27)$$

284 For GAS, we require $\dot{V} < 0$ for all $t \geq 0$. We note that the first two terms on the right hand side of (27) have no
285 dependence on r ; thus if these two terms together are negative, then by an appropriate selection of α we can always
286 make \dot{V} negative. We therefore can simplify the analysis by considering

$$287 \quad \dot{\hat{V}} = a^T [qW - B^{-1}(\Sigma + K)a + qWp] + p^T [((1 - q)W - B^{-1}\Sigma)a + ((1 - q)W - B^{-1}\Gamma)p]. \quad (28)$$

288 Applying a completion of squares and algebraic simplifications we can show the condition $\dot{\hat{V}} < 0$ to be equivalent to

289 the inequality

$$290 \quad \begin{bmatrix} a^T & p^T \end{bmatrix} \begin{bmatrix} qW & \frac{1}{2}W \\ \frac{1}{2}W & (1-q)W \end{bmatrix} \begin{bmatrix} a \\ p \end{bmatrix} < \begin{bmatrix} a^T & p^T \end{bmatrix} \begin{bmatrix} B^{-1}(\Sigma + K) & -\frac{1}{2}B^{-1}\Sigma \\ -\frac{1}{2}B^{-1}\Sigma & B^{-1}\Gamma \end{bmatrix} \begin{bmatrix} a \\ p \end{bmatrix}. \quad (29)$$

291 In the case where $1 \geq r_c > 0$, we can apply a basic translation. The result then follows from Theorem 4.2 in [42]. Note
 292 that directly from (27), the condition in (20) is also sufficient for GAS in cases with permanent immunity ($\Delta = 0$). ■

293 Summarizing, (23) provides a test that bounds the maximum eigenvalue of the q -scaled adjacency matrix W in
 294 terms of the minimum eigenvalue of a matrix consisting of diagonal block entries of ratios of healing and transition
 295 rates (κ_i , γ_i and σ_i) to infection rates (β_i). This condition generalizes the usual R_0 threshold to allow for heterogeneous
 296 infection parameters over multiple infection compartments in the N-SAIRS model form.

297 **Remark 1.** Note that in the case of a slightly simpler spread process model, for example for a networked SIRS model,
 298 a sufficient condition for convergence to the DFE would be $\lambda_{\max}(W) < \lambda_{\min}(B^{-1}\Gamma) = \min_i(\gamma_i/\beta_i) = \min_i(1/R_{0i})$.

299 3 Parameter estimation

300 In this section we discuss a simple least-squares approach for model parameter estimation for a discrete-time N-SAIRS
 301 model, given below in (30), and present some of our initial estimation results from local data for COVID-19. We also
 302 provide an overview of the approach we have used to estimate asymptomatic proportions of the subpopulations of
 303 interest.

304 The data sets we consider result from sampling on a daily basis, thus a discrete-time model is better suited for es-
 305 timating and evaluating model parameters. We first apply a forward Euler's method to the continuous-time networked
 306 model in (20), and appropriately scale the model by N_i for each subpopulation, giving us the discrete-time N-SAIRS

307 model,

$$\begin{aligned}
 a_i^{k+1} &= a_i^k + q\beta_i(N_i - a_i^k - p_i^k - r_i^k) \sum_j \frac{W_{ij}}{N_j} (a_j^k + p_j^k) - \sigma_i a_i^k - \kappa_i a_i^k \\
 p_i^{k+1} &= p_i^k + (1-q)\beta_i(N_i - a_i^k - p_i^k - r_i^k) \sum_j \frac{W_{ij}}{N_j} (a_j^k + p_j^k) + \sigma_i a_i^k - \gamma_i p_i^k \\
 r_i^{k+1} &= r_i^k + \kappa_i a_i^k + \gamma_i p_i^k - \delta_i r_i^k,
 \end{aligned}$$

309 where $\{a_i, p_i, r_i\}$ represent the population of asymptomatic, symptomatic-infected and recovered individuals in region
 310 i respectively, $\forall i \in [n]$. Since our simulation update also will be daily and the sampling rate is once-per-day, the
 311 sampling parameter typically made explicit in such sampled-data models will be 1 and thus is not explicitly noted
 312 above.

313 3.1 Least Squares Estimation

314 When the proportion q of the asymptomatic infections is known or estimated, we can apply a simple least squares
 315 (LS) approach, for example as outlined in [43] and further described for SAIRS models in [20], to estimate the model
 316 parameters $\beta_i, \sigma_i, \kappa_i, \gamma_i$, and δ_i . Our initial estimation step is therefore to estimate q .

317 3.1.1 Estimating the Asymptomatic Population Proportion

318 Due to the difficulties in identifying and monitoring infected individuals without symptoms, explicit and unbiased
 319 information for asymptomatic-infected estimations is not always available. We have applied Nesterov's Next-Day Law
 320 to estimate the daily number of asymptomatic individuals, based on a constant latent infectious period assumption, and
 321 further to estimate the proportion q of the asymptomatic infections as a fraction of the total population. We note that,
 322 more precisely stated, this approach gives us a pre-symptomatic subpopulation proportion. We state the Next-Day
 323 Law here for completeness.

324 **Proposition 3.** [44] Let $T(d)$ represent the total number of confirmed cases by day d , and $A(d)$ represent the number
 325 of asymptomatic infected individuals at the beginning of day d . Assume the latent period (the time between exposure
 326 and onset of symptoms) is a constant time of Δ days. Then, $A(d+1) = T(d+\Delta) - T(d), \forall d \in \mathbb{Z}$

327 From estimated daily asymptomatic numbers, the proportions q and $1 - q$ corresponding to the asymptomatic and
 328 symptomatic infections, can be approximated.

329 As observed in many data sets for COVID-19 (for example, in the testing data posted by the Champaign-Urbana
 330 Public Health Department, Illinois), the infected (both asymptomatic and symptomatic) and recovered populations are
 331 relatively much smaller than the susceptible population. Therefore, the third and fourth terms in the first two equations
 332 in (30) are assumed to be negligible compared to the second term. Omitting these terms gives us the approximate
 333 relationship

$$334 \frac{a_i^{k+1} - a_i^k}{p_i^{k+1} - p_i^k} \approx \frac{q}{1 - q}, \quad (30)$$

335 from which we can approximate

$$336 q \approx \frac{a_i^{k+1} - a_i^k}{(a_i^{k+1} - a_i^k) + (p_i^{k+1} - p_i^k)}. \quad (31)$$

337 3.1.2 Estimation of Model Parameters

338 Given an estimated, or a known value, for q , we can now rewrite the networked system (30) as a system of linear
 339 equations. Let

$$340 \quad b := \begin{bmatrix} a_i^1 - a_i^0 \\ \vdots \\ a_i^T - a_i^{T-1} \\ p_i^1 - p_i^0 \\ \vdots \\ p_i^T - p_i^{T-1} \\ r_i^1 - r_i^0 \\ \vdots \\ r_i^T - r_i^{T-1} \end{bmatrix}, \quad \mathcal{A} := \begin{bmatrix} \Phi_i \\ \Sigma_i \\ \Gamma_i \end{bmatrix}, \quad x := \begin{bmatrix} \beta_i \\ \sigma_i \\ \gamma_i \\ \kappa_i \\ \delta_i \end{bmatrix},$$

341 with

$$\begin{aligned}
 342 \quad \Phi_i &:= \begin{bmatrix} qs_i^0 \sum_j W_{ij}(a_j^0 + p_j^0) & -a_i^0 & 0 & -a_i^0 & 0 \\ \vdots & \vdots & \vdots & \vdots & \vdots \\ qs_i^{T-1} \sum_j W_{ij}(a_j^{T-1} + p_j^{T-1}) & -a_i^{T-1} & 0 & -a_i^{T-1} & 0 \end{bmatrix}, \\
 343 \quad \Sigma_i &:= \begin{bmatrix} (1-q)s_i^0 \sum_j W_{ij}(a_j^0 + p_j^0) & a_i^0 & -p_i^0 & 0 & 0 \\ \vdots & \vdots & \vdots & \vdots & \vdots \\ (1-q)s_i^{T-1} \sum_j W_{ij}(a_j^{T-1} + p_j^{T-1}) & a_i^{T-1} & -p_i^{T-1} & 0 & 0 \end{bmatrix}, \\
 344 \quad \Gamma_i &:= \begin{bmatrix} 0 & 0 & a_i^0 & p_i^0 & -r_i^0 \\ \vdots & \vdots & \vdots & \vdots & \vdots \\ 0 & 0 & a_i^{T-1} & p_i^{T-1} & -r_i^{T-1} \end{bmatrix} \\
 345
 \end{aligned}$$

346 where $s_i^k = N - a_i^k - p_i^k - r_i^k, \forall i \in [n], k \in \mathbb{Z}$.

347 Then the discrete-time N-SAIRS model can be written as

$$348 \quad \mathcal{A}x = b \quad \forall i \in [n] \tag{32}$$

349 Since q is assumed known, (32) is linear with respect to the remaining model parameters. When \mathcal{A} is full rank,
 350 we can thus recover the parameters β_i^* , σ_i^* , γ_i^* , κ_i^* , and δ_i^* using a standard least-squares solution to (32).

351 3.2 Preliminary estimation results

352 For our preliminary parameter estimation, local COVID-19 testing-site data from Champaign County, Illinois, dating
 353 from April to September, 2020, is used. We obtained data from the Champaign-Urbana Public Health District web-
 354 site (publicly available at <https://www.c-uphd.org/champaign-urbana-illinois-coronavirus-information.html>), which is
 355 updated daily and includes the total accumulative number of infected (lab-confirmed), recovered, hospitalized, and
 356 deceased individuals for Champaign county, as well as current number of actively infected (lab-confirmed) individuals
 357 over 34 zip code areas within the county. We scraped the website data on a daily basis manually from April 2020 to
 358 March 2022, storing the daily accumulative infected, actively-infected, and recovered populations for each zip code in

359 a Google Sheet [45]. Preliminary estimates are presented from the initial wave of COVID-19 in Champaign County,
360 where we consider different phases of the epidemic according to the Illinois State Restore plan, specifically:

361 *Phase 1 : Rapid Spread* April 01, 2020 - April 31, 2020

362 *Phase 2 : Flattening* May 01, 2020 - May 29, 2020

363 *Phase 3 : Recovery* May 30, 2020 - June 26, 2020

364 *Phase 4 : Revitalization* June 27, 2020 - September 26, 2020
365

366 We assume a latent period of $\Delta = 6$ days, giving estimated parameter values:

Phases	q	β	σ	γ	κ	R_0
Phase 2	0.7	0.06	0.22	0.15	-0.10	1.004
Phase 3	0.6	0.07	0.15	0.15	-0.05	1.156
Phase 4	0.6	0.07	0.08	0.11	0.02	1.104

368
369 Estimated local Sars-CoV-2 paramters

370 For comparison, we computed an asymptomatic infection proportion q using Peoria County medical clinics data
371 [46], containing COVID-19-related records of all individuals who visited one of eight medical clinics in Peoria and
372 Pekin from April to June 2020. The Peoria clinic data explicitly includes records of the COVID-19 test results, as
373 well as all symptoms described by the patient to the provider, for each visiting individual. The computed values for
374 proportion q for Phase 2 and Phase 3 in the Peoria data are approximately 0.51 and 0.42, respectively, both of which
375 are lower than the values estimated from the Champaign County data. This difference is not unexpected, given that
376 patients visited the Peoria clinics because they were experiencing symptoms of illness, although these may have been
377 illnesses other than COVID-19.

378 We note that, as the epidemic progresses, the basic reproduction number R_0 first increases, and then decreases due
379 to the implementation of quarantine and other social distancing measures. The preliminary results also expose issues
380 with data-based estimation and analysis early in an epidemic. For example, due to the limited available testing in the
381 early stage of the epidemic we have a non-random population sample, thus the testing population presented in the data

382 is skewed toward Symptomatic-Infected individuals. This hinders us from accurately capturing the true proportion of
383 the Asymptomatic-Infected subgroup, as well as an accurate prevalence of the epidemic over the total population [47].
384 In addition, our assumption of a constant latent period is not consistent with viral infections, including COVID-19; the
385 latent period value we have chosen is thus an average value taken from [48,49]. These issues lead to estimation errors,
386 in particular note the negative values for recovery rate κ in Phase 1 and Phase 2. For this reason, estimated values
387 from the larger virology and epidemiology literature are evaluated and used in our simulation studies.

388 4 Simulations

389 In this section, we illustrate the dynamics associated with endemicity, and the roles of the asymptomatic subgroup
390 and contact network in the progression of the epidemic. We follow this with a multi-stage forecast of an epidemic
391 spread process with both pharmaceutical and non-pharmaceutical mitigation approaches, as well as a simulation of an
392 endemic COVID-19 process under annual vaccinations.

393 First, we simulate a baseline N-SAIRS model based on (4), for which we assume homogeneous spread parameters
394 and a five-subpopulation network structure. We assume the total population size is 10,000 and the respective sub-
395 populations denoted A, B, C, D, and E have populations of 2000, 2500, 1500, 3500, and 500 people, respectively. In
396 this baseline simulation we assume the subpopulations are fully connected with evenly distributed edge weights, thus
397 this model is equivalent to the single group model represented in (3). We use the estimation results from early local
398 data (discussed in Section 3) in addition to drawing upon the literature on COVID-19 (e.g., [48, 50–52]) to inform our
399 baseline model parameter value selection, specifically setting $(q, \beta, \sigma, \gamma, \kappa, \delta) = (0.7, 0.25, 0.15, 0.11, 0.08, 0.0001)$.

400 These values represent the original strain of SARS-CoV-2. Note these parameters roughly correspond to an in-
401 fectionous disease with a duration of symptomatic infection of 9 days, duration of asymptomatic infection of 12 days,
402 duration of pre-symptomatic infection of 6 days, and duration of immunity following recovery from infection of 30
403 years, or essentially permanent immunity. We further set the initial proportions of the A, I, R compartments as

$$a(0) = (a_A(0), a_B(0), a_C(0), a_D(0), a_E(0)) = (0.006, 0.004, 0.012, 0.004, 0.004)$$

$$p(0) = (p_A(0), p_B(0), p_C(0), p_D(0), p_E(0)) = (0.005, 0.002, 0.008, 0.003, 0.002)$$

$$r(0) = (r_A(0), r_B(0), r_C(0), r_D(0), r_E(0)) = (0.007, 0.003, 0.010, 0.008, 0.005)$$

Simulating the SAIRS model over 60 days results in the epidemic progression shown in Fig 1. Note that peak active

Figure 1: Group/Network SAIRS Simulation: Baseline Model

405
 406 infection occurs on day 33, that is $p(t) + a(t)$ attains a maximum of approximately 28% on day $t = 33$. By day
 407 60, approximately 87% of the entire population has been or is infected; assuming a mortality rate of 2% would
 408 correspond to 174 deaths in the two month time span. Again we note this model assumes homogeneous mixing
 409 within the entire population. We will use this baseline model to compare to situations where immunity following
 410 recovery is not permanent, leading to endemicity and to potential virus mutations yielding multi-strain/multi-stage
 411 viral processes [53].

412 **4.1 Endemicity**

413 As presented in Proposition 2, the condition for endemicity (that is, GAS of the endemic equilibrium) is given by

$$414 \quad C = \beta(q\gamma + (1 - q)\kappa + \sigma) - \gamma(\kappa + \sigma) > 0, \quad (33)$$

415 and

$$416 \quad R_{end} = \frac{(CD + D^2)(\delta + F)\Phi(F\Phi - \Psi) - D^2\Psi(F\Phi - \Psi) + \delta(\delta + F)(C^2 + CD)\Phi^2 + \delta CD\Phi(F\Phi - \Phi^2 - \Psi)}{CD\Psi\Phi^2} > 1, \quad (34)$$

417 where D , F , Φ and Ψ are given in the preceding section.

418 Note that the condition $C > 0$ for the existence of an endemic equilibrium is equivalent to the condition that $R_0 > 1$.
 419 It can be observed that, with values for all other parameters unchanged, R_{end} increases monotonically as the value for
 420 the model parameter δ increases. Setting the initial conditions and parameters as in the baseline model, excepting a
 421 change in the parameter value of δ , simulation results depicting endemic equilibria corresponding to different R_{end}
 thresholds are presented in Figures 2, 3, 4.

Figure 2: Endemicity with $\delta = 0.001$, corresponding to immunity following infection of approximately 2.8 years.

422

423 As the value for R_{end} increases with increasing δ value, the oscillations before reaching the endemic equilibrium

Figure 3: Endemicity with $\delta = 0.01$, corresponding to immunity following infection of approximately 3 months.

Figure 4: Endemicity with $\delta = 0.1$, corresponding to immunity following infection of approximately 10 days.

424 have smaller amplitude, although they may have higher frequency. For the models with parameters $\delta = 0.001$, $\delta =$
425 0.01 , $\delta = 0.1$, the first oscillatory dip in the R (recovered) subgroup occurs at approximately 850 days, 160 days and
426 55 days, respectively, and the amplitude differences in the proportions of the recovered subgroups between the first
427 peaks to the following lowest points are approximately 0.45, 0.22, 0.015, respectively. Comparing the population
428 proportions for the endemic equilibria points in these three models, as the value for δ increases, the proportion of
429 R decreases, whereas proportions for A and I increase. This observation coincides with the expression of endemic
430 equilibria presented in (10), in Section 2.

431 4.2 Asymptomatic Effects

432 One major obstacle in the control of COVID-19 has been the challenge of identifying and monitoring individuals
433 in the asymptomatic but infectious subgroup. Herein we explore the impact of the asymptomatic subgroup on the
434 epidemic evolution. We first assume no control actions are imposed on either the asymptomatic or symptomatic
435 infected subgroups, for example, imposing isolation or masking policies. For simplicity, we use the group model (3)
436 with the same parameter values as in our baseline model, which gives a basic reproduction number $R_0 \approx 2.5$ from (7).
437 By setting initial proportions for the A, I, R compartments as

$$438 \quad (a(0), I(0), R(0)) = (0.004, 0.002, 0.003), \quad (35)$$

we obtain the 90-day simulation results shown in Fig 5. The population reaches a peak infection level of approximately

Figure 5: No control policies in effect on either Asymptomatic or Symptomatic Infected subgroups

439
440 25% on day 35. By day 80, approximately 87% of the population has been or is infected.

441 Next, we implement moderate and stringent isolation policies on only the symptomatic subgroup; this is effected
442 in the simulations by changing the respective infection rate parameters of the subgroups, which we now denote indi-

443 vidually by β_A and β_I . Imposing isolation policies on a subgroup effectively lowers the corresponding infection rate.
The simulation results are shown in Fig 6. We note that with isolation measures on only the symptomatic infected

(a) Moderate isolation of Symptomatic-Infected subgroup; $\beta_A = 0.25, \beta_I = 0.11$ giving effective $R_0 = 1.5$
(b) Stringent isolation of Symptomatic-Infected subgroup; $\beta_A = 0.25, \beta_I = 0.06$ giving effective $R_0 = 1.2$

Figure 6: Imposing isolation policies on subgroup I

444
445 subgroup, the epidemic now progresses more slowly and mildly, as is expected, however there is still substantial infec-
446 tion in the population. The infection peaks at days 60 and 75, respectively, approximately 4 – 6 weeks later than with
447 no control. With moderate isolation policies in effect on the I subgroup, the peak infection level is approximately 9%
448 and with strict isolation policies the peak infection level attained is approximately 2.5%. Finally by day 80, the total
449 percentages of the population that have been or are infected is approximately 49% and 17%; with a mortality rate of
450 2% this corresponds to 98 and 34 deaths, respectively.

451 Alternatively, we consider the situation where Asymptomatic individuals are also identified and isolated, under
both moderate and stringent policies, with the results shown in Fig 7.

(a) Moderate isolation of both Symptomatic- and Asymptomatic- (b) Stringent isolation of both Symptomatic- and Asymptomatic-
Infected subgroups; $\beta_A = 0.11, \beta_I = 0.11$ giving effective $R_0 = 1.09$ Infected subgroups; $\beta_A = 0.0125, \beta_I = 0.0125$ giving effective $R_0 = 0.12$

Figure 7: Imposing isolation policies on subgroups A and I

452
453 Note that, with only moderate isolation on both Asymptomatic and Symptomatic Infected subgroups (7a), the
454 epidemic is under control within three months. By day 80, approximately 7.7% of the population has been or is
455 infected, corresponding to a total of 770 individuals in a population base of 10,000; at a 2% mortality rate this
456 corresponds to approximately 15 – 16 deaths as compared to approximately 34 deaths with stringent control imposed
457 on only the Symptomatic Infected subgroup (6b).

458 An additional perspective to consider is the effective reproduction number under the different isolation policies.
459 Moderate isolation of both Asymptomatic and Symptomatic subgroups (7a) gives an effective $R_0 \approx 1.09$, while strin-
460 gent isolation on just the Symptomatic subgroup (6b) gives an effective $R_0 \approx 1.2$.

461 These simulation results confirm the obvious: identification and isolation of Asymptomatic infected individuals is
462 much more effective in curbing the spread of the epidemic than identification and isolation of only the Symptomatic

463 subgroup. To achieve this goal, either regular extensive mandatory testing policies, or persistent isolation of the whole
464 population, is required.

465 4.3 Network Effects

466 Here, we evaluate the effect that a more realistic interaction structure has on epidemic spread over a population. We
467 consider the 5-node network introduced earlier, and consider the removal of a small number of edges between nodes,
468 corresponding to there being no interaction between certain subpopulations. We first consider an interconnection
469 network structure with adjacency matrix

$$470 \quad W = \begin{bmatrix} \frac{1}{3} & \frac{1}{3} & \frac{1}{3} & 0 & 0 \\ \frac{1}{3} & \frac{1}{3} & 0 & 0 & \frac{1}{3} \\ \frac{1}{3} & 0 & \frac{1}{3} & \frac{1}{3} & 0 \\ 0 & 0 & \frac{1}{2} & \frac{1}{2} & 0 \\ 0 & \frac{1}{2} & 0 & 0 & \frac{1}{2} \end{bmatrix}. \quad (36)$$

471 Using the same parameters and initial conditions as in the baseline model, our simulations return results as shown in
Fig 8 for subpopulations C and E, for example.

(a) Subpopulation C

(b) Subpopulation E

Figure 8: Densely Connected Network Simulation Results

472

(a) Subpopulation 4

(b) Subpopulation 22

(c) Subpopulation 28

(d) Subpopulation 32

(e) Subpopulation 34

(f) Subpopulation 48

Figure 9: Sparsely Connected Network Simulation Results

473 With an incomplete network structure, the epidemic spreads more slowly and weakly. Subpopulation C reaches its
474 peak infection level at day 37, and subpopulation E at day 39. By day 60, approximately 83% of area C population
475 and 81% of area E population have been infected. However, in total, approximately 480 fewer individuals over the
476 five areas are infected as compared to the fully connected (i.e., complete) baseline model.

477 To explore the impact of quarantine and stronger social distancing measures, we further break the full popula-
478 tion into 50 smaller subpopulations, and generate a stochastic adjacency matrix with each node only connected to
479 (randomly selected) 20 other nodes out of the total of 50 group nodes. We also generated the initial proportions ran-
480 domly, i.e., $a(0), p(0), r(0)$, assuming $a_i(0) \sim \mathcal{N}(0.04, 0.005)$, $p_i(0) \sim \mathcal{N}(0.02, 0.005)$, $r_i(0) \sim \mathcal{N}(0.03, 0.005)$,
481 with these values restricted to be non-negative. Randomly selecting 6 of the 50 sub-populations, we present a sample
482 of the simulation results as shown in Fig 9:

483 Note that, with this more extensive isolation structure, the epidemic decays much faster than under the previous
484 densely connected network (Fig 8). Subpopulations 4, 22, 28, 32, 34 and 48, respectively, reach their peak infection
485 levels at days 21, 59, 7, 24, 0 and day 8. Among the six subpopulations in the sample, subpopulation 22 is the most
486 highly infected group. However, overall after 60 days, approximately only 13.6% of the population has been or
487 is infected, which is a reduction of 73.4% of the population compared to the fully connected network (Fig 1), and
488 a reduction of 67.7% compared to the strongly connected network (Fig 8). These simulations confirm that social
489 distancing measures, such as quarantining within each community or family, does serve to slow the spread of the
490 epidemic. From the perspective of the group model, extensive isolation policies do help reduce the group transmission
491 rate for person-to-person contact, although these do not completely halt the disease spread.

492 We also investigate the impacts of different underlying network structures on the stability of the DFE and endemic
493 equilibria. As shown in (23) in Section 2, the bound provided on the eigenvalues of the q -scaled adjacency matrix W
494 by the eigenvalues of a matrix generated by diagonal block entries of ratios of recovery and transition rates (symptoms
495 onsetting) to infection rates gives a sufficient condition for the stability of the DFE. We consider the equilibria for the
496 full population under different interconnection network structures. Evaluating endemic equilibria, for all $i \in [n]$, we
497 set the homogeneous spread parameter values to

$$498 \quad (q, \beta_i, \gamma_i, \kappa_i, \sigma_i, \delta_i) = (0.7, 0.15, 0.11, 0.08, 0.15, 0.01). \quad (37)$$

499 The convergence results of the networked models (4) with a 5-node densely connected network (36), a 50-node fully
500 connected network and a 50-node sparsely connected network are illustrated in Fig 10, yielding the simulation results
501 shown over 700 days.

502 On one hand, the maximum eigenvalue of the fully connected graph (10a) and densely connected graph (10b)

- (a) Fully connected network
(b) Densely connected network
(c) Sparsely connected network

Figure 10: DFE convergence for N-SAIRS models

503 are both approximately 1.04. This value is larger than the minimum eigenvalue of the parameters matrix, which is
504 approximately 0.49. In both network structures, the systems converge to the endemic equilibrium. On the other hand,
505 the maximum eigenvalue of the sparsely connected graph (10c), which is approximately 0.25, is smaller than the
506 minimum eigenvalue of the parameters matrix. With this network structure, the system converges to the DFE. These
507 simulation results serve as examples of the condition derived in (23). Note that (23) is not a necessary condition for
508 convergence to the DFE. That is, violation of this condition does not guarantee that the system will converge to an
509 endemic equilibrium.

510 **4.4 A Multi-stage Simulation**

511 In addition to non-pharmaceutical measures, such as mask policies and social distancing, pharmaceutical measures
512 such as vaccinations and treatment of symptoms clearly also play important roles in the control of epidemic spread
513 processes. With the increasingly availability of vaccines for COVID-19 since March 2021, the number of daily new
514 cases of COVID-19 has dropped, even with less strict social distancing amongst populations [54, 55]. However, the
515 overall effect of these vaccinations may be compromised by virus mutations [56, 57]. In this section, taking both
516 vaccines and virus mutations into consideration, we present a multi-stage group SAIRS simulation representing the
evolution of COVID-19 in Illinois in Fig 11; the relevant timeline is also given.

Figure 11: Multi-stage (3-year) SAIRS process with Vaccinations and Virus Mutations

517

518 *Stage 1 : Rapid Spread (45 days : Day 1 – Day 45)*

519 *Stage 2 : Flattening: Lockdown (70 days : Day 46 – Day 115)*

520 *Stage 3 : Restoration: Social distancing, masking, reduced indoor capacities (135 days : Day 116 – Day 250)*

521 *Stage 4 : Re-enacted Restrictions: $\frac{1}{2}$ of all regions (15 days : Day 251 – Day 265)*

522 *Stage 5 : Re-enacted Restrictions: all regions (90 days : Day 266 – Day 355)*

523 *Stage 6 : Vaccination rollout: (90 days : Day 356 – Day 445)*

524 *Stage 7 : Variant 1 Emergence: (210 days : Day 446 – Day 655)*

525 *Stage 8 : Booster rollout: (30 days : Day 656 – Day 685)*

526 *Stage 9 : Variant 2 Emergence: (145 days : Day 686 – Day 830)*

527 *Stage 10 : Social Distancing Lifted, Waning Vaccine Immunity: (170 days : Day 831 – Day 1000)*

528

529 We have again considered the baseline group model

$$\dot{S}(t) = -(p\beta_v + (1-p)\beta_{uv})S(t)(A(t) + I(t)) + \delta R(t)$$

$$\dot{A}(t) = q(p\beta_v + (1-p)\beta_{uv})S(t)(A(t) + I(t)) - \sigma A(t) - \kappa A(t)$$

530

$$\dot{I}(t) = (1-q)(p\beta_v + (1-p)\beta_{uv})S(t)(A(t) + I(t)) + \sigma A(t) - \gamma I(t)$$

$$\dot{R}(t) = \kappa A(t) + \gamma I(t) - \delta R(t),$$

531 p is the vaccination level, and β_v , β_{uv} , respectively, are the transmission rates between infected and non-infected
532 individuals who have or have not been vaccinated, respectively. Assuming that the immunity individuals gain after
533 infection or vaccination lasts one year, we set the baseline model parameter values based on COVID-19 literature for
534 the United States up to June 2021 as

535

$$(\beta_{uv}, \beta_v, q, v, \sigma, \gamma, \kappa, \delta) = (0.2, 0.0001, 0.7, 0.7, 0.075, 0.14, 0.15, 0.003),$$

536 Different β_{uv} values are implemented throughout the simulation for different levels of social distancing. In Stage 6,
537 the vaccination level p is set to increase at the beginning of each sub-stage. Specifically, $p = 0.2$ for day 1-day 30;
538 $p = 0.4$ for day 31-day 60, $p = 0.5$ for day 61-day 90, in reference to the first day of vaccination rollout. In Stage 7,
539 both β_{uv} and β_v are set to be higher than the original baseline transmission rates due to the highly contagious nature of
540 the new variant, and the receding immunity provided by the vaccines as time passes.

541 As shown in Figure 11, the lockdown in Stage 2 effectively mitigates the spread of the epidemic, whereas the
542 relaxation of social distancing policies results in a slight surge in infection rates starting from approximately day
543 240. This coincides with the network results previously presented in Section 4.3. Vaccination in Stage 6 successfully
544 mitigates the spread of the epidemic, however, a new surge arises with the emergence of new variants starting from
545 approximately day 450, which attains a peak infection level of approximately 13.5% on day 510. To reinforce the effect
546 of the first round of vaccines, in Stage 8 booster shots are provided, which facilitate the mitigation of the epidemic.
547 The effectiveness of these booster shots are again undermined as a more contagious variant of the virus emerges on day
548 685. Despite being highly contagious, this new variant appears to result in less severe symptoms among vaccinated
549 individuals, which results in faster recoveries compared to the previous virus strains. As the immunity gained from
550 vaccines recedes over time and social distancing policies are lifted, individuals become more exposed to new variants
551 and therefore have higher chances of being infected or reinfected, resulting in another surge in the infection level
552 during stage 10.

553 Further, we simulated a five-year glance into the future where the epidemic of COVID-19 potentially becomes
554 endemic, and updated booster vaccines are provided annually, similar to current influenza practices; this is shown in
555 Fig 12.

Figure 12: Endemic SAIRS with Annual Vaccinations

556 We have again updated model parameter values as

$$557 \quad (\beta_{uv}, \beta_v, q, \sigma, \gamma, \kappa, \delta) = (0.5, 0.2, 0.5, 0.75, 0.15, 0.1, 0.005)$$

558 based on the COVID-19 literature up to September 2022 (e.g. [58–61]), where Omicron (B.1.1.529) is the main variant
559 of the endemic epidemic. We also assume the effectiveness of the annual vaccines decreases by 10% every two months

560 based on [62]. This corresponds to 100% effectiveness during the first two months following vaccination, and 50%
561 effectiveness over the last two months until getting the next annual vaccination. We set the initial proportions for the
562 A, I, R compartments as

$$563 \quad (a(0), I(0), R(0)) = (0.018, 0.03, 0.5) \quad (38)$$

564 based on the proportions at the end of Multi-stage simulation (Fig 11) and [63]. Fig 12 shows periodic oscillations in
565 both the recovered population (R : attaining local peaks at day 64, day 347, day 642, day 996, day 1356 and day 1721)
566 and the infected populations ($A + I$: attaining local peaks at day 21, day 287, day 576, day 924, day 1284 and day
567 1648), for which the frequency and amplitude decreases over time until eventually reaching the endemic equilibria.
568 This observed epidemic behavior coincides with the behavior of the endemic evolution as simulated in Figures 2,3,4.

569 **5 Conclusions and Future Work**

570 In this paper, we have briefly reviewed classical epidemiological compartment models, with a focus on a new SAIR(S)
571 model that emphasizes the role played by the Asymptomatic-infected subpopulation. We presented continuous-time,
572 discrete-time, and networked versions of the SAIR(S) model, and discuss their corresponding equilibria and stability
573 properties. We have noted the use of Nesterov's Next-Day Law and a basic least-squares approach for model parameter
574 estimation, and conducted initial parameter estimation for COVID-19 using publicly available data from Champaign
575 County, Illinois. Furthermore, we completed simulations of both group and networked models investigating the impact
576 of isolating subpopulations, highlighting the crucial role of the Asymptomatic subgroup in the control of epidemic
577 evolution, and exploring long-term endemicity conditions.

578 In the estimation process, we have encountered many challenges, most significantly biased testing data and the lack
579 of explicit information on the asymptomatic infected population. Our ongoing efforts include pursuing more complete
580 endemic equilibria analyses for the N-SAIR(S) model and investigating approaches for model estimation under non-
581 random and missing sample data sets, for example as described in [64]. We are further investigating Bayesian statistical
582 methods for estimating true prevalence of epidemics given biased information for apparent prevalence [65].

583 Acknowledgments

584 The authors would like to thank Dr. Joseph Kim, M.D., Ph.D., for many useful and interesting discussions, and for
585 providing informative references.

586 References

- 587 [1] Yin Q, Shi T, Dong C, Yan Z. The impact of contact patterns on epidemic dynamics. PLOS ONE. 2017.
- 588 [2] Oliva G, Schlueter M, Munetomo M, Scala A. Dynamical intervention planning against COVID-19-like epi-
589 demics. PLOS ONE. 2022.
- 590 [3] Kermack WO, McKendrick AG. Contributions to the mathematical theory of epidemics. II. The problem of
591 endemicity. Proceedings of the Royal Society A. 1932;138(834):55–83.
- 592 [4] Bernoulli D. Essai d’une nouvelle analyse de la mortalité causée par la petite vérole et des avantages de
593 l’inoculation pour la prévenir. Histoire de l’Acad Roy Sci avec Mém des Math et Phys and Mém. 1760:1–45.
- 594 [5] Scarpino SV, Petri G. On the predictability of infectious disease outbreaks. Nature communications. 2019;10.
- 595 [6] Funk S, Gilad E, Watkins C, Jansen VAA. The spread of awareness and its impact on epidemic outbreaks.
596 Proceedings of The National Academy of Sciences. 2009;106:6872–6877.
- 597 [7] Granell C, Gómez S, Arenas A. Dynamical Interplay between Awareness and Epidemic
598 Spreading in Multiplex Networks. Phys Rev Lett. 2013 Sep;111:128701. Available from:
599 <http://link.aps.org/doi/10.1103/PhysRevLett.111.128701>.
- 600 [8] Paarporn K, Eksin C, Weitz JS, Shamma JS. Networked SIS Epidemics with Awareness. IEEE Trans Computa-
601 tional Social Systems. 2017;4(3):93–103.
- 602 [9] Liu J, Paré PE, Nedić A, Beck CL, Başar T. On a continuous-time multi-group bi-virus model with human
603 awareness. In: Proceedings of The IEEE Conference on Decision and Control; 2017. p. 4124–4129.


- 604 [10] Xu S, Lu W, Zhan Z. A Stochastic Model of Multivirus Dynamics. *IEEE Transactions on Dependable and Secure*
605 *Computing*. 2012;9(1):30–45.
- 606 [11] Paré PE, Liu J, Beck CL, Nedić A, Başar T. Multi-Competitive Viruses over Static and Time-Varying Networks.
607 In: *Proceedings of American Control Conference*; 2017. p. 1685–1690.
- 608 [12] Paré PE, Liu J, Beck CL, Nedić A, Basar T. Multi-Competitive Viruses over Time-Varying Networks with
609 Mutations and human Awareness. *Automatica*. 2021;123.
- 610 [13] Li G, Zhang Y. Dynamic behaviors of a modified SIR model in epidemic diseases using nonlinear incidence and
611 recovery rates. *PLOS ONE*. 2017.
- 612 [14] Kephart JO, White SR. Directed-graph epidemiological models of computer viruses. In: *IEEE Symposium on*
613 *Security and Privacy*; 1991. p. 343–361.
- 614 [15] Newman ME. Spread of epidemic disease on networks. *Phys Rev E Stat Nonlin Soft Matter Phys*. 2002 06;66.
- 615 [16] Ganesh A, Massouli L, Towsley D. The effect of network topology on the spread of epidemics. In: *24th Annual*
616 *Joint Conference of the IEEE Computer and Communications Societies*. vol. 2; 2005. p. 1455–1466.
- 617 [17] Draief M, Massoulié' L. *Epidemics and rumours in complex networks*. Cambridge University Press; 2010.
- 618 [18] Pastor-Satorras R, Castellano C, Van Mieghem P, Vespignani A. Epidemic processes in complex networks.
619 *Reviews of Modern Physics*. 2015;87(3):925.
- 620 [19] Nowzari C, Preciado VM, Pappas GJ. Analysis and control of epidemics: A survey of spreading processes on
621 complex networks. *IEEE Control Systems Magazine*. 2016;(1):26–46.
- 622 [20] Pare P, Beck CL, Başar T. Modeling, Estimation, and Analysis of Epidemics over Networks: An Overview.
623 *Annual Reviews in Control*. 2020;50:345–360.
- 624 [21] Zhao D, Wang L, Li S, Wang Z, Wang L, Gao B. Immunization of Epidemics in Multiplex Networks. *PLOS*
625 *ONE*. 2014.
- 626 [22] Feller W. On the Integro-Differential Equations of Purely Discontinuous Markoff Processes. *Transactions of the*
627 *American Mathematical Society*. 1940;48(3):488–515.


- 628 [23] Kurtz TG. The Central Limit Theorem for Markov Chains. *The Annals of Probability*. 1981;9(4):557–560.
- 629 [24] Mieghem PV, Omic J, Kooij R. Virus spread in networks. *IEEE/ACM Transactions on Networking*. 2009;(1):62–
630 68.
- 631 [25] Chatterjee S, Durrett R. Contact processes on random graphs with power law degree distributions have critical
632 value 0. *The Annals of Probability*. 2009;(6):2332–2356.
- 633 [26] Fall A, Iggidr A, Sallet G, Tewa JJ. Epidemiological models and Lyapunov functions. *Mathematical Modelling
634 of Natural Phenomena*. 2007;2(1):62–83.
- 635 [27] Paré PE, Beck CL, Nedić A. Epidemic Processes over Time-Varying Networks. *IEEE Transactions on Control
636 over Network Systems*. 2018;(3):1322–1334.
- 637 [28] Ahn HJ, Hassibi B. Global dynamics of epidemic spread over complex networks. In: *Proceedings of the IEEE
638 Conference on Decision and Control*; 2013. p. 4579–4585.
- 639 [29] Wang Y, Chakrabarti D, Wang C, Faloutsos C. Epidemic spreading in real networks: an eigenvalue viewpoint.
640 In: *Proceedings of the 22nd International Symposium on Reliable Distributed Systems*; 2003. p. 25–34.
- 641 [30] Khanafer A, Başar T, Gharesifard B. Stability properties of infected networks with low curing rates. In: *Pro-
642 ceedings of the American Control Conference*; 2014. p. 3579–3584.
- 643 [31] Khanafer A, Başar T, Gharesifard B. Stability properties of infection diffusion dynamics over directed networks.
644 In: *Proceedings of the IEEE Conference on Decision and Control*; 2014. p. 6215–6220.
- 645 [32] Nowzari C, Preciado VM, Pappas GJ. Stability analysis of generalized epidemic models over directed networks.
646 In: *Proceedings of the IEEE Conference on Decision and Control*; 2014. p. 6197–6202.
- 647 [33] Health Care Engineering Systems Center U. COVID-19 Virtual Summit; 2020. April 6.
- 648 [34] NeTs Community N, the Ohio State University. First Call to Arms Workshop; 2020. April 13.
- 649 [35] Bi X, Beck CL. On the Role of Asymptomatic Carriers in Epidemic Spread Processes. *arXiv*. 2021 March.
650 ArXiv:2103.11411.


- 651 [36] Grunnill M. An exploration of the role of asymptomatic infections in the epidemiology of dengue viruses
652 through susceptible, asymptomatic, infected and recovered (SAIR) models. *Journal of Theoretical Biology*.
653 2018;439:195–204.
- 654 [37] Zhu L, Wang B. Stability analysis of a SAIR rumor spreading model with control strategies in online social
655 networks. *Information Science*. 2020;526.
- 656 [38] Hota A, Sneha T, Gupta K. Impacts of Game-Theoretic Activation on Epidemic Spread over Dynamical Networks.
657 arXiv. 2020 Nov. ArXiv2011.00445v1 [physics.soc-ph].
- 658 [39] Dobrovolny HM. Modeling the role of asymptomatics in infection spread with application to SARS-CoV-2.
659 *PLOS ONE*. 2020.
- 660 [40] Paiva HM, Afonso RJM, Oliveira IL, Garcia GF. A data-driven model to describe and forecast the dynamics of
661 COVID-19 transmission. *PLOS ONE*. 2020.
- 662 [41] Stella L, Martinez AP, Bauso D, Colanari P. The Role of Asymptomatic Individuals in the COVID-19 Pandemic
663 via Complex Networks. arXiv. 2020 Sept. ArXiv:2009.03649v1 [physics.soc-ph].
- 664 [42] Khalil HK. *Nonlinear Systems*. Prentice Hall; 2002.
- 665 [43] Paré PE, Liu J, Beck CL, Kirwan BE, Başar T. Analysis, Identification, and Validation of Discrete-Time Epidemic
666 Processes. *IEEE Transactions on Control Systems Technology*. 2019;28(1):79–93.
- 667 [44] Nesterov Y. Online prediction of COVID19 dynamics. Belgian case study. LIDAM Discussion Papers CORE.
668 2020.
- 669 [45] Bi X, Dekhterman S, Beck CL. Champaign County SARS-CoV-2 Test Site Data. figshare; 2023.
670 <http://doi.org/10.6084/m9.figshare.21902580>.
- 671 [46] Peoria SARS-CoV-2 clinic data. figshare; 2023. <https://doi.org/10.6084/m9.figshare.21903072>.
- 672 [47] Hoff V. Estimation of Hidden Carriers of Infectious Diseases [Master's thesis]. University of Illinois at Urbana-
673 Champaign; 2022. Available from: <http://www.ideals.illinois.edu/items/124464>.


- 674 [48] Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus
675 Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of*
676 *Internal Medicine*. 2020.
- 677 [49] Oran DP, E J Topol M. Prevalence of Asymptomatic SARS-CoV-2 Infection; A Narrative Review. *Annals of*
678 *Internal Medicine*. 2020.
- 679 [50] Ling Y, Xu S, Lin Y, Tian D, Zhu Z, Dai F, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus
680 disease rehabilitation patients. *Chinese Medical Journal*. 2020;133.
- 681 [51] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel
682 Coronavirus–Infected Pneumonia. *N Engl J Med*. 2020;382.
- 683 [52] Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2
684 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020;382.
- 685 [53] Paré PE, Liu J, Beck CL, Nedić A, Başar T. Multi-Competitive Viruses over Time–Varying Networks with
686 Mutations and Human Awareness. 2020.
- 687 [54] Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks in the United
688 States. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2021
689 Jan.
- 690 [55] Evine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation
691 with the BNT162b2 vaccine. *Nature Medicine*. 2021 March.
- 692 [56] Bernal JL, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *The New England*
693 *Journal of Medicine*. 2021 July.
- 694 [57] Bian L, Gao F, Zhang J, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies.
695 *Expert review of vaccines*. 2021 April.


- 696 [58] Centers for Disease Control and Prevention. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within
697 Households — Four U.S. Jurisdictions, November 2021–February 2022. *Morbidity and Mortality Weekly Re-*
698 *port*. 2022 03.
- 699 [59] Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times
700 relative to Delta. *Journal of Travel Medicine*. 2022 05.
- 701 [60] Pulliam JRC, Schalkwyk CV, Govender N, Gottberg AV, Cohen C, Groome MJ, et al. Increased risk of SARS-
702 CoV-2 reinfection associated with emergence of Omicron in South Africa. *Science*. 2022 05.
- 703 [61] Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The Impact of Vaccination
704 on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. *Clinical Infectious Diseases*. 2021
705 01;73(12):2257–2264.
- 706 [62] Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness
707 of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-
708 regression. *The lancet*. 2022 05.
- 709 [63] Centers for Disease Control and Prevention. Nationwide COVID-19 Infection-Induced Antibody Seroprevalence
710 (Commercial laboratories); 2022. Data retrieved from COVID Data Tracker.
- 711 [64] Copas JB, Li HG. Inference for non-random samples. *Journal of the Royal Statistical Society*. 1997;59(1):55–95.
- 712 [65] Bi X, Miehling E, Beck CL, Başar T. Approximate Testing in Uncertain Epidemic Processes. In: *Proceedings of*
713 *the IEEE Conference on Decision and Control*; 2022. .

































Fully connected network



Densely connected network



Sparsely connected network

